Brief: MaxCyte Announces Strategic Platform Licensing Agreement With Anocca AB To Advance Tcr-T Cell Therapy Pipeline
31/07/2025 14:41
July 31 (Reuters) - MaxCyte Inc MXCT.O: MAXCYTE ANNOUNCES STRATEGIC PLATFORM LICENSING AGREEMENT WITH ANOCCA AB TO ADVANCE TCR-T CELL THERAPY PIPELINE Source text: ID:nGNX1GsYrb Further company coverage: MXCT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsCell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted
Brief: MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
MaxCyte Inc reports results for the quarter ended June 30 - Earnings Summary
MaxCyte Q2 revenue beats estimates
MaxCyte Inc expected to post a loss of 9 cents a share - Earnings Preview